Compare Aurora Cannabis Inc (ACB) vs Upstart Holdings Inc (UPST) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Upstart trades at $33.06, down 4.95% today, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported $1.02B revenue in 2025 with net income of $53.60M, marking a return to profitability after previous losses. Recent news highlights AI lending growth and a $600M funding deal with Neuberger (Business Wire, June 24, 2026).

Outlook is cautiously optimistic with a consensus price target of $43.00 (45% buy ratings), but risks include volatile cash flows, high debt-to-asset ratio of 61.48%, and execution challenges in expanding auto/home lending products. The stock offers upside if AI-driven originations sustain growth, yet remains sensitive to funding and macroeconomic conditions.